And continual clearance of plaque psoriasis flare-ups through week 82,†,‡
Wynzora delivers fast improvements as early as week 1 and continual benefit through week 8 with significant reductions in pruritus1,2,5,*,†See efficacy data
Optimized skin penetration of Cal and BDP with PADTM Technology: Cal adds to the anti-inflammatory effect of BDP to reduce the characteristic scaling of psoriasis and restore epidermal barrier function3,4,6Explore the MOA
Less than 1% of patients experienced application-site irritation with Wynzora5View safety
The safety and efficacy of Wynzora cream were evaluated in a randomized, multicenter, noninferiority, vehicle- and active comparator–controlled clinical trial in adult patients with mild-to-moderate plaque psoriasis. In the trial, 794 patients were randomized to 1 of 3 treatment groups: Wynzora cream, vehicle cream, or Cal/BDP TS, 0.005%/0.064%. The majority of patients in the trial (81.7%) had disease of moderate severity at baseline, while 18.3% of patients had disease of mild severity. Disease severity was determined by a 5-grade PGA scale.7
The primary efficacy endpoint was the proportion of patients with treatment success at week 8. Treatment success was defined as at least a 2-grade improvement from baseline in the PGA score and a PGA score equating to “clear” or “almost clear.” Other evaluated outcomes included a reduction in itch as defined by at least a 4-point improvement in the 11-point NRS from baseline to week 4.7
BDP: betamethasone dipropionate; Cal: calcipotriene; NRS: Peak Pruritus Numerical Rating Scale; PGA: Physician Global Assessment; TS: topical suspension.
*Wynzora cream (36.0%) demonstrated a ≥1-grade PGA improvement in significantly more patients than vehicle (12.6%) at week 1 (P<0.0001).1
†Wynzora cream (37.4%) was noninferior to calcipotriene/betamethasone dipropionate topical suspension, 0.005%/0.064% (22.8%) for the primary endpoint of treatment success at week 8.7
‡When used as directed.
§At participating pharmacies. Limitations apply. Reduced copay for commercially insured eligible patients. Uninsured and government-insured patients are not eligible for these offers. See rebate card for details.